KR20080109094A - 조류 인플루엔자 백신 및 이용방법 - Google Patents

조류 인플루엔자 백신 및 이용방법 Download PDF

Info

Publication number
KR20080109094A
KR20080109094A KR1020087027929A KR20087027929A KR20080109094A KR 20080109094 A KR20080109094 A KR 20080109094A KR 1020087027929 A KR1020087027929 A KR 1020087027929A KR 20087027929 A KR20087027929 A KR 20087027929A KR 20080109094 A KR20080109094 A KR 20080109094A
Authority
KR
South Korea
Prior art keywords
asn
leu
ser
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087027929A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 로버트 웨브
매튜 제이 헨리
Original Assignee
다우 아그로사이언시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다우 아그로사이언시즈 엘엘씨 filed Critical 다우 아그로사이언시즈 엘엘씨
Publication of KR20080109094A publication Critical patent/KR20080109094A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020087027929A 2006-04-21 2007-04-20 조류 인플루엔자 백신 및 이용방법 Withdrawn KR20080109094A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/793,804 2006-02-10
US79380406P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
KR20080109094A true KR20080109094A (ko) 2008-12-16

Family

ID=39402309

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027929A Withdrawn KR20080109094A (ko) 2006-04-21 2007-04-20 조류 인플루엔자 백신 및 이용방법

Country Status (9)

Country Link
US (1) US7993655B2 (enExample)
EP (1) EP2010210A4 (enExample)
JP (1) JP2009535306A (enExample)
KR (1) KR20080109094A (enExample)
CN (1) CN101578111A (enExample)
AR (1) AR060565A1 (enExample)
BR (1) BRPI0710689A2 (enExample)
CA (1) CA2650091A1 (enExample)
WO (1) WO2008060669A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540801A (ja) * 2006-06-16 2009-11-26 ダウ・アグロサイエンス・エル・エル・シー トリインフルエンザ赤血球凝集素の新規なdna配列、ベクターおよびタンパク質
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
KR20100006574A (ko) 2007-05-30 2010-01-19 사무엘 보고치 수산 양식되는 무척추동물의 병원체 감염에 대항하는 합성 레플리킨 펩티드
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
SG187500A1 (en) * 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
DK2294202T3 (en) 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
SG10201401532PA (en) * 2009-04-23 2014-08-28 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
SI2445928T1 (en) 2009-06-24 2018-05-31 Medicago Inc. HYPER PARTICULARS, SIMILAR VIRUSES OF GRIPE, WHICH HAVE EXPOSED HEMAGLUTININE
SG178918A1 (en) 2009-09-22 2012-04-27 Medicago Inc Method of preparing plant-derived vlps
EP2515661A4 (en) * 2009-12-23 2013-11-13 Vaxgene Corp IMMUNE PROTECTION THROUGH ORAL ADMINISTRATION OF MINI-CAPSULES WITH RECOMBINANT LACTOCOCCUS LACTIS
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
WO2013013075A2 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
AU2013204906B2 (en) * 2012-03-12 2016-01-07 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
AU2013359146B2 (en) 2012-12-13 2017-12-07 Corteva Agriscience Llc DNA detection methods for site specific nuclease activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885248A (en) 1984-02-15 1989-12-05 Lubrizol Genetics, Inc. Transfer vector
US5173410A (en) 1984-02-15 1992-12-22 Lubrizol Genetics Inc. Transfer vector
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
ATE108828T1 (de) 1987-02-09 1994-08-15 Lubrizol Genetics Inc Hybrides rns-virus.
WO1991009957A1 (en) 1989-12-22 1991-07-11 E.I. Du Pont De Nemours And Company Site-specific recombination of dna in plant cells
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
JPH07200893A (ja) 1993-12-27 1995-08-04 Toshiba Corp 自動精算機
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
JP2000253876A (ja) * 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US6855536B2 (en) 2000-07-20 2005-02-15 University Of Tennessee Research Corp., Inc. Materials and methods for the enhancement of effective root nodulation in legumes
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
DE10061150A1 (de) 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10109354A1 (de) 2001-02-27 2002-09-05 Icon Genetics Ag Rekombinante virale Schaltersysteme
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
CN1533438A (zh) 2001-06-08 2004-09-29 �����Ŵ��Ƽ���˾ 在植物生产蛋白质的方法
DE10129010A1 (de) 2001-06-13 2002-12-19 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
DE10143205A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Verfahren zur Proteinproduktion in Pflanzen
ES2329450T3 (es) 2002-04-29 2009-11-26 Icon Genetics Gmbh Proceso para producir organismos transgenicos ambientalmente seguros.
NZ542933A (en) * 2003-05-05 2009-08-28 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
DE602004027403D1 (de) 2003-11-10 2010-07-08 Icon Genetics Ag Von rna-virus abgeleitetes pflanzenexpressionssystem

Also Published As

Publication number Publication date
EP2010210A2 (en) 2009-01-07
US20090136532A1 (en) 2009-05-28
WO2008060669A2 (en) 2008-05-22
CA2650091A1 (en) 2008-05-22
AR060565A1 (es) 2008-06-25
WO2008060669A3 (en) 2009-05-07
US7993655B2 (en) 2011-08-09
BRPI0710689A2 (pt) 2012-02-22
CN101578111A (zh) 2009-11-11
JP2009535306A (ja) 2009-10-01
EP2010210A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
US7993655B2 (en) Vaccine for avian influenza and methods of use
EP2721158B1 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
US8163876B2 (en) DNA sequences, vectors and proteins of avian influenza hemagglutinin
ES2752323T3 (es) Partículas de tipo virus que comprenden proteínas diana fusionadas a proteínas de revestimiento de virus vegetales
US10358652B2 (en) Influenza virus-like particle production in plants
EP2814837B1 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
EA034733B1 (ru) Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
BR112014023900A2 (pt) Polipeptídeo de hemaglutimina de influenza recombinante, molécula de ácido nucleicoisolada, vetor, célula isolada, partícula semelhante ao vírus da influenza, proteína de fusão, composição, e uso
JP2013533270A (ja) インフルエンザワクチン
KR102027758B1 (ko) 약독화된 돼지 인플루엔자 백신 및 이의 제조 방법 및 용도
KR20140090137A (ko) 인플루엔자 h5 백신
EP2925773B1 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
JP7858592B2 (ja) インフルエンザbウイルス変異体およびその使用
Szurgot et al. Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform
Stepanova et al. Amino acid substitutions N123D and N149D in hemagglutinin molecule enhance immunigenicity of live attenuated influenza H7N9 vaccine strain in experiment
CN104726416B (zh) 提供流感病毒异源保护的病毒样颗粒及其方法和应用
Košík et al. A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection
US20180016560A1 (en) Novel influenza virus
AU2007319715A1 (en) Vaccine for avian influenza and methods of use
CA1270438A (en) Influenza vaccine
EP4676529A2 (en) Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
Cornelissen et al. A Single Immunization with Soluble Recombinant Trimeric
Glueck New Strategies to Overcome the Drawbacks ofCurrently Available Flu Vaccines
HK1177692B (en) Novel influenza virus
HK1197685B (en) Computationally optimized broadly reactive antigens for h1n1 influenza

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20081114

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101025

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20101224

WITB Written withdrawal of application